The evolving challenge of persistent symptoms post-Coronavirus disease-2019 (COVID-19), particularly debilitating cardio-pulmonary manifestations, necessitates further exploration. Our study aimed to assess the cardio-pulmonary complications in patients a year after hospital discharge from severe COVID-19, contrasting these with findings from a non-COVID group. The OneCoV2 study, a prospective, case-control study, was conducted at a tertiary care teaching hospital in northern India. We enrolled 43 subjects, with a mean age of 25.57 ± 7.94 years (COVID group) and 27.30 ± 8.17 years (non-COVID group). Comprehensive tests included pulmonary function tests, cardiac function tests, 6-min walk tests, and laboratory investigations. Significant differences were found in the pulmonary function [forced vital capacity (FVC) (p = 0.037), forced expiratory flow (FEF) 25-75 % (p = 0.013)], and cardiac function [left ventricular ejection fraction (LVEF) (p = 0.032), heart rate (HR) (p = 0.047)], along with the six-minute walk test results between the two groups. In the COVID group, Pearson's correlation showed a negative correlation between FVC and C-reactive protein (CRP) [r = -0.488, p = 0.007] and a positive correlation between the six-minute walk test [r = 0.431, p = 0.003] and HR [r = 0.503, p = 0.013]. Our data suggest that pulmonary abnormalities are prevalent in COVID patients even after 1-year of hospital discharge. Cardiac biomarkers also show an inclination towards the COVID group. While we found significant correlations involving some parameters like FVC, CRP, HR, and results from the six-minute walk test, we did not find any significant correlations with the other tested parameters in our study.

The association between frailty and health-related quality of life (HRQoL) among Asian patients with liver cirrhosis and sarcopenia remains largely unexplored. To address this knowledge gap, we conducted a cross-sectional study involving individuals aged 32 to 69 years, all diagnosed with liver cirrhosis. The chronic liver disease questionnaire (CLDQ) was used to assess HR-QoL, the CLDQ score was used as an outcome to measure the factors related to HR-QoL, and the liver frailty index (LFI) was used to assess the frailty status. The association between the frailty status and the CLDQ summary scales was investigated using the correlation coefficient and multiple regression analyses. A total of 138 patients in the frail (n = 62) and non-frail (n = 76) groups with (alcohol: 97; viral: 24; autoimmune: 17; and cryptogenic: 12) were included in the study. Age, CTP score, and model for end-stage liver disease (MELD) sodium were significantly higher in the frail group. In the CLDQ domains, there was a significant difference between the frail and non-frail groups (p value = 0.001). In health-related quality-of-life summary measures, there was a strong negative correlation between frailty and the scores for activities, emotional function, and fatigue (p value = 0.001). When comparing frail to non-frail patients, these characteristics demonstrated significantly increased odds as indicated by their adjusted odds ratios: OR 3.339 (p value = 0.013), OR 3.998 (p value = 0.006), and OR 4.626 (p value = 0.002), respectively.

Background: Frailty is a critical concern for chronic kidney disease (CKD) patients, contributing to increased vulnerability to adverse health outcomes and diminished quality of life. However, there is limited research on frailty’s impact on health-related quality of life (HRQOL) among dialysis and pre-dialysis patients in the Indian context. Methods: This study involved participants aged 18 and above with CKD stages 3–5. Frailty was assessed using the Morley FRAIL questionnaire, and HRQOL was measured using the RAND version of the KDQOL-36 Survey. Data were analyzed with SPSS version 29, focusing on the association between frailty and HRQOL domains. Results: Among the 147 CKD patients, 56.46% were frail, and 43.56% were non-frail. Significant differences were noted between frail and non-frail groups in age (p = 0.036), CKD stages (p < 0.001), nutritional status (p < 0.001), Charlson comorbidity index (p < 0.001), BMI (p < 0.001), GFR (p < 0.001), CRP (p = 0.006), and serum albumin (p = 0.002). Frailty is significantly associated with lower physical (p < 0.001) and mental (p < 0.001) quality of life. Negative associations between frailty and KDQOL-36 domains, especially symptom problems, PCS, and MCS, were established. Conclusions: Our findings emphasize the importance of frailty screening in CKD patients. Early identification may help guide targeted strategies to support HRQOL. However, longitudinal studies are needed to assess frailty progression and the impact of potential interventions.